Astec Lifesciences (BOM:533138) Cyclically Adjusted Revenue per Share: ₹300.57 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:533138 Astec Lifesciences Ltd BOM:533138
74 GF Score
Price ₹602.70
GF Value ₹903.29
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Astec Lifesciences Cyclically Adjusted Revenue per Share?

Astec Lifesciences BOM:533138 +0.25% 74 Cyclically Adjusted Revenue per Share is ₹300.57 as of Jun. 2026. GuruFocus rates BOM:533138 with a GF Score™ of 74/100 and a GF Value™ of ₹903.29 (Significantly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Astec Lifesciences's adjusted revenue per share for the three months ended in Jun. 2026 was ₹37.501. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹300.57 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Astec Lifesciences's average Cyclically Adjusted Revenue Growth Rate was 3.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Astec Lifesciences was 10.40% per year. The lowest was 4.10% per year. And the median was 6.30% per year.

As of today (2026-08-24), Astec Lifesciences's current stock price is ₹602.70. Astec Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹300.57. Astec Lifesciences's Cyclically Adjusted PS Ratio of today is 2.01.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Astec Lifesciences was 8.38. The lowest was 1.83. And the median was 4.71.


Astec Lifesciences  (BOM:533138) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Astec Lifesciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=602.70/300.57
=2.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Astec Lifesciences was 8.38. The lowest was 1.83. And the median was 4.71.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Astec Lifesciences Cyclically Adjusted Revenue per Share Related Terms


Astec Lifesciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Astec Lifesciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astec Lifesciences Cyclically Adjusted Revenue per Share Chart

Astec Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 235.55 262.63 277.31 283.51 296.28

Astec Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 287.74 288.91 294.97 296.28 300.57

BOM:533138 vs CTVA, CF, MOS: Cyclically Adjusted Revenue per Share Comparison

For the Agricultural Inputs subindustry, Astec Lifesciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astec Lifesciences Cyclically Adjusted PS Ratio vs Agriculture Industry

For the Agriculture industry and Basic Materials sector, Astec Lifesciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Astec Lifesciences's Cyclically Adjusted PS Ratio falls into.


BOM:533138
74GF Score
Astec Lifesciences Ltd BOM:533138
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astec Lifesciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astec Lifesciences's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=37.501/167.3573*167.3573
=37.501

Current CPI (Jun. 2026) = 167.3573.

Astec Lifesciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 43.521 105.961 68.738
201612 30.623 105.196 48.718
201703 43.723 105.196 69.559
201706 34.168 107.109 53.387
201709 48.658 109.021 74.694
201712 37.681 109.404 57.641
201803 65.115 109.786 99.261
201806 33.002 111.317 49.616
201809 57.126 115.142 83.032
201812 60.555 115.142 88.016
201903 67.842 118.202 96.055
201906 39.142 120.880 54.192
201909 71.106 123.175 96.611
201912 63.249 126.235 83.853
202003 91.567 124.705 122.885
202006 56.708 127.000 74.728
202009 78.506 130.118 100.974
202012 58.723 130.889 75.084
202103 87.031 131.771 110.535
202106 65.093 134.084 81.246
202109 51.950 135.847 64.000
202112 87.734 138.161 106.274
202203 137.733 138.822 166.045
202206 93.200 142.347 109.575
202209 101.127 144.661 116.993
202212 59.552 145.763 68.375
202303 64.270 146.865 73.238
202306 72.314 150.280 80.531
202309 56.093 151.492 61.967
202312 25.707 152.924 28.133
202403 77.510 153.035 84.764
202406 35.113 155.789 37.720
202409 50.245 157.882 53.260
202412 47.858 158.323 50.589
202503 60.924 157.552 64.716
202506 46.454 159.755 48.665
202509 34.254 162.289 35.324
202512 55.941 163.281 57.338
202603 71.160 164.272 72.496
202606 37.501 167.357 37.501

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹300.57 mean?
Astec Lifesciences (BOM:533138) has a Cyclically Adjusted Revenue per Share of ₹300.57 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Astec Lifesciences and its competitors.
Is Astec Lifesciences' Cyclically Adjusted Revenue per Share too high?
Astec Lifesciences' current Cyclically Adjusted Revenue per Share is ₹300.57. Overall, Astec Lifesciences has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astec Lifesciences' Cyclically Adjusted Revenue per Share compare to CTVA and CF?
Astec Lifesciences' Cyclically Adjusted Revenue per Share of ₹300.57 can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for an Agriculture company?
A good Cyclically Adjusted Revenue per Share depends on the Agriculture industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Astec Lifesciences and its competitors. Astec Lifesciences's current Cyclically Adjusted Revenue per Share is ₹300.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astec Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Astec Lifesciences (BOM:533138) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹903.29, compared to a current price of ₹602.70 — trading 33.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹300.57. Astec Lifesciences' overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Astec Lifesciences (BOM:533138), the current Cyclically Adjusted Revenue per Share is ₹300.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astec Lifesciences (BOM:533138) Overvalued in 2026?

Based on GuruFocus' analysis, Astec Lifesciences stock appears to be undervalued. The current stock price of ₹602.70 is trading 33.3% below its estimated GF Value™ of ₹903.29. GuruFocus considers Astec Lifesciences to be Significantly Undervalued.

Key valuation signals for BOM:533138:

  • Cyclically Adjusted Revenue per Share: ₹300.57
  • GF Value™: ₹903.29 vs. price of ₹602.70 (33.3% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the BOM:533138 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Astec Lifesciences Business Description

Other Exchanges ASTEC:India
Address Eastern Express Highway, Godrej One, 3rd Floor, Pirojshanagar, Vikhroli (East), Mumbai, MH, IND, 400 079
Astec Lifesciences Ltd manufactures & distributes a wide range of Agrochemical active ingredients and pharmaceutical intermediates. The company's products include agrochemicals, such as Triazole Fungicides, Herbicides, and Insecticides. The company is also into Intermediates & Specialty chemicals. Geographically, all the operations of the firm function through India; however, its products are sold in the Indian and overseas markets. It operates in the business segment of Agrochemicals and has a business presence in India and outside India.
74GF Score

Get the complete analysis for BOM:533138

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹602.70
Price
₹903.29
GF Value